Sustaining Rapid Medicine Development
Lessons From A Pandemic
The Economist Impact Report: Biopharma’s evolution: learnings from the pandemic for a revived regulatory landscape
Can drug developers and regulators create a sustainable culture that allows the biopharma industry to continue to work with the accelerated model adopted during the COVID-19 pandemic, or will industry burnout ensue?
![Biopharma's Evolution Economist Impact Biopharma’s evolution: learnings from the pandemic for a revived regulatory landscape](/deepweb/assets/sigmaaldrich/marketing/global/images/campaign/biopharmas-evolution/economist-impact/economist-impact.jpg)
This report examines the following questions:
- What will the biopharma regulatory science landscape look like in 2027?
- What role will governments, regulators, and investors play in boosting the ecosystem for biopharma innovation, including sustainability targets?
- Which therapeutic areas and technologies lend themselves to biopharma industry collaboration?
- What will accelerate innovation cycles and regulatory approvals post-pandemic?
- How will regulators deal with digitalization, artificial intelligence and machine learning in the drug approval process?
The art of the possible: reimagining the biopharmaceutical supply chain
October 4th, 2022 10 am EDT/ 3pm BST
![<p> Meeta Gulyani Head of Strategy, Business Development and Sustainability, Life Science MilliporeSigma Meeta Gulyani Head of Strategy, Business Development and Sustainability, Life Science MilliporeSigma](/deepweb/assets/sigmaaldrich/marketing/global/images/campaign/biopharmas-evolution/m-gulyani/m-gulyani.jpg)
Meeta Gulyani Meeta Gulyani Head of Strategy, Business Development and Sustainability, Life Science MilliporeSigma
![<p>Vice President, Supply Chain AbbVie Mike Douma Vice President, Supply Chain AbbVie](/deepweb/assets/sigmaaldrich/marketing/global/images/campaign/biopharmas-evolution/m-douma/m-douma.jpg)
Mike Douma Vice President, Supply Chain AbbVie
![<p>Partner, McKinsey Tacy Foster Partner McKinsey](/deepweb/assets/sigmaaldrich/marketing/global/images/campaign/biopharmas-evolution/t-foster/t-foster.jpg)
Tacy Foster Partner, McKinsey
![<p> Senior Vice President, Policy and Research PhRMA Anne McDonald Pritchett Senior Vice President, Policy and Research PhRMA](/deepweb/assets/sigmaaldrich/marketing/global/images/campaign/biopharmas-evolution/a-mcdonald-pritchett/a-mcdonald-pritchett.jpg)
Anne McDonald Pritchett Senior Vice President, Policy and Research PhRMA
![<p> Senior Manager, Health, Policy and Insights Economist Impact Alan Lovell Senior Manager, Health, Policy and Insights Economist Impact](/deepweb/assets/sigmaaldrich/marketing/global/images/campaign/biopharmas-evolution/a-lovell/a-lovell.jpg)
Alan Lovell Senior Manager, Health, Policy and Insights Economist Impact
Programmed by Economist Impact and sponsored by Merck, The art of the possible: reimagining the biopharmaceutical supply chain will examine what leaders in the biopharmaceutical supply chain must do to steer their businesses through a time of rapid change and ongoing disruption, and identify synergies and efficiencies to bring drugs to market more effectively.
계속 읽으시려면 로그인하거나 계정을 생성하세요.
계정이 없으십니까?